News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article details a Form 144 SEC filing by Regeneron Pharmaceuticals, Inc. (REGN) on August 10, 2026. The filing indicates a proposed sale of 800 shares of common stock acquired through the exercise of stock options on the same day, with an aggregate market …
Sharemaestro market context Price above Trend Line 52 weeks +24.3% · Next-week setup negative 36.4%This article reports on a Form 144 SEC filing by Regal Rexnord Corp (RRX) on August 10, 2026. The filing indicates a proposed sale of 170 shares of common stock with an aggregate market value of $29,960.41, acquired through restricted stock vesting. The filing …
Regions Financial Corp (RF) has filed its quarterly Form 13F Holdings Report, disclosing 1,041 reportable equity positions with an aggregate value of $16.75 billion as of the reporting date. The filing consolidates holdings from Regions Bank, Regions Investment Management, Inc., and Highland Associates Inc. …
BMO Capital has increased its price target for Regency Centers (REG) to $92 from $90, while maintaining an Outperform rating on the stock. This adjustment reflects continued positive sentiment from the analyst firm towards the commercial REIT. The article notes that access to the …
Argus has raised its price target for Regency Centers (REG) to $85 from $81, while maintaining a Buy rating on the stock. This adjustment reflects an updated outlook on the commercial REIT. Another analyst, BMO Capital, also recently adjusted its price target for Regency …
Regeneron Pharmaceuticals, Inc. (REGN), a major biotechnology firm with an $80.75 billion market cap, shows a 6.27% upside potential according to analysts. The company exhibits robust financial health with 16.70% revenue growth and over $3 billion in free cash flow, supported by strategic partnerships …
Pacer Advisors Inc. significantly reduced its stake in Regions Financial Corporation (NYSE:RF) by 50.5% in the first quarter, selling 44,501 shares and retaining 43,648 shares valued at approximately $1.14 million. Despite this, institutional investors collectively own 79.39% of RF. Regions Financial recently reported strong …
Contravisory Investment Management Inc. acquired 10,147 shares of Regeneron Pharmaceuticals (NASDAQ:REGN) valued at approximately $6.3 million during the second quarter. Regeneron reported strong quarterly earnings, surpassing analyst estimates with $14.29 EPS and $4.29 billion in revenue, and declared a quarterly dividend of $0.94 per …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Regal Rexnord (RRX) is back in focus after its second quarter 2026 report, which featured higher sales, higher net income and updated full year earnings guidance that …
Regional Management (RM) reported Q2 2026 earnings with total revenue up 6.7% year-over-year to $168 million, primarily from higher net finance receivables, while diluted EPS decreased 17.5% to $0.85 due to increased credit loss provision and interest expense. The company is strategically shifting towards …
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Regencell Bioscience Holdings Ltd. (NASDAQ:RGC) and its officers. The lawsuit, filed on behalf of investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, alleges the company made materially …
Faruqi & Faruqi, LLP is reminding investors of Regeneron (NASDAQ:REGN) about an upcoming September 14, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, which …
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ:RGNX) on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO made materially false and misleading statements regarding the development …
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased securities between August 1, 2023, and May 15, 2024. The lawsuit alleges that Regeneron made materially false and misleading statements and …
Sharemaestro market context Price above Trend Line 52 weeks +24.3% · Next-week setup negative 36.4%Bank of America Corp DE reduced its stake in Regions Financial Corporation (NYSE:RF) by 1.1% in the first quarter, selling 37,751 shares but still retaining a significant holding of 3.47 million shares. Despite this sale, institutional investors collectively own 79.39% of RF. Analysts currently …
Wall Street Zen downgraded Regional Management (NYSE:RM) from a "buy" to a "hold" rating, though the consensus among analysts remains a "Moderate Buy" with an average price target of $43.00. The company recently exceeded Q2 earnings and revenue estimates, reporting $0.85 EPS on $168.01 …
Regal Rexnord Corporation's stock dropped 13% despite reporting a 29% EPS beat in its second-quarter report, with statutory earnings per share at US$1.74. Analysts are maintaining their revenue and EPS forecasts for 2026, expecting US$6.21 billion in revenue and US$5.66 EPS, indicating no significant …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Dividend, earnings and buybacks in focus Regeneron Pharmaceuticals (REGN) has given investors several fresh data points to consider after confirming a quarterly dividend, releasing …
Sharemaestro market context Price above Trend Line 52 weeks +24.3% · Next-week setup negative 36.4%Regency Centers (REG) has announced quarterly cash dividends for its common and preferred stock, following a period of positive share price performance and slightly raised full-year guidance. The stock is currently trading below analyst targets and an intrinsic fair value, suggesting it might be …
REGENXBIO (RGNX) experienced a nearly 5% stock drop despite reporting a surprise profit of US$0.43 EPS and US$108 million in revenue for Q2 2026, swinging from a significant loss. The company also extended its cash runway into Q4 2027 due to funding from AbbVie …
This article provides an analyst report on Regeneron Pharmaceuticals, Inc. (REGN), highlighting its strong growth and pipeline progress. The company specializes in developing and commercializing treatments for various diseases, including eye disease, cardiovascular disease, cancer, and inflammation, with key marketed products like low-dose Eylea …
Sharemaestro market context Price above Trend Line 52 weeks +24.3% · Next-week setup negative 36.4%Royal Bank of Canada significantly increased its stake in Regency Centers Corporation (NASDAQ:REG) by 45.9% in the first quarter of 2026, holding 189,131 shares valued at $14.3 million. Institutional investors collectively own a substantial 96.07% of REG, indicating strong institutional interest. The company maintains …
PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 17.6% in the second quarter, acquiring 3,619 additional shares. The investment firm now owns 24,190 shares of REGN, valued at approximately $15.1 million. This comes amid mixed signals for Regeneron, including strong quarterly earnings, …
Regency Centers director C. Ronald Blankenship was granted 167 shares of common stock on August 7, 2026, as director's fees under the company's Omnibus Incentive Plan. Following this stock award, Blankenship directly holds a total of 114,923 shares of Regency Centers common stock. This …
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has filed a Form 13F holdings report as an institutional investment manager, detailing three reportable investment positions. The aggregate value of these holdings totals $177,219,142. The report indicates no other managers are included in this filing.
Regency Centers Corporation (NASDAQ:REG) has declared a quarterly dividend of $0.755 per share, payable on October 2nd to shareholders of record on September 11th, which represents an annualized yield of approximately 3.9%. Despite a current payout ratio of 123.8% exceeding earnings, analysts anticipate improved …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Greggs sits at the centre of a fresh price target debate, with recent analyst work clustering around £19.60 and £22.10 per share. These …
Analysts have raised REGENXBIO Inc.'s average 12-month price target from $26 to $26.17, indicating a potential upside of approximately 149% from its August 5 closing price. The consensus rating for RGNX remains a "Buy" among 12 analysts, with 11 recommending a Buy and 1 …
Search by ticker symbol or company name and select a result to open its chart.